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1. Introduction 
It is noteworthy to consider that extensive bioavailability and bioequivalence studies are 
typically required before new drug therapies can be approved [1]. These studies include 
pharmacokinetic studies that take into account: 1) dosing, absorption, and elimination rates 
of the drug and its active metabolites, as well as 2) the potential effects of multiple doses, 
drug interactions, and the differences whether medications are taken with or without food. 
A major therapeutic factor that compounds the variations often seen from patient to patient 
is individual differences in absorption and elimination rates. This will also cause variations 
in the amount of drug that reaches the desired targeted tissue when used as a clinical 
therapy. 
While oral administrations are common and the easiest means to deliver outside of a 
hospital or clinical setting, intravenous (IV) delivery can eliminate some of the 
aforementioned patient to patient variability by bypassing the ingestion and absorption into 
a patient’s bloodstream. However, a major obstacle with either of these delivery methods is 
that once a drug is in the blood plasma, the medication will circulate throughout the 
patient’s body, not only reaching the intended site, but unintended sites as well. Hence, this 
will greatly increase the possibility of causing unwanted side effects. Thus, it is required that 
side effects on each and every tissue be well described when therapeutic levels of the 
medication are administered. 
Importantly, many drugs have described narrow therapeutic ranges. Slight increases in 
levels could cause severe undesired effects, whereas slight decreases often eliminate any 
therapeutic benefit. We describe in detail here how the targeted and local delivery of 
medications may overcome many of these obstacles in traditional delivery methods by 
simplifying the pharmacokinetics, reducing variability, and allowing higher doses to reach 
the intended target. 
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1.1. Targeted drug delivery 
“Targeted drug delivery” is a general term that describes a variety of methods that can be 
used to increase the concentrations of a given drug at a primary location within the body 
relative to other body tissues. Often called “smart therapies,” targeted delivery includes 
methods such as antibody labeling, ultrasonic release, and/or localized delivery that can 
increase drug concentrations at the desired tissue. The primary intent is to increase the 
intended beneficial effects while reducing side effects. 
Developments in targeted drug delivery were commonly pioneered with anti-cancer drugs. 
These treatments are often highly toxic and have undesirable side effects, which in turn can 
greatly reduce quality of life and limit the dose levels that can be administered. Therefore, if 
the levels of these drugs can be increased specifically at the site of a tumor relative to the 
rest of the body, the same or reduced dose levels will have much greater effects at the site of 
the cancerous tumor. 
One commonly described method for accomplishing this is creating or adding components 
to cancer drugs that preferentially bind within the tumors. More specifically, the 
identification of differences in endothelial surfaces in growing tumors has led to the 
development of cancer medications that preferentially adhere to the endothelial surfaces 
within the vasculature of the tumor, thus increasing the desired effects. This results in lower 
exposures of non-target tissues to the drug than were previously possible. In a similar 
manner, numerous biomarkers have been identified that become upregulated in diseased 
cardiac tissue, and therefore have become targets in emerging therapies [2], [3]. 
Alternatively, drug treatments can be encapsulated in such a way that they are released at 
the desired location, such as where triggered by high frequency ultrasound, causing focal 
increases in drug concentrations [4–6]. Table 1 summarizes many currently used and 
investigated targeted therapies, several of which are described in greater detail throughout 
this chapter. 
1.2. Localized delivery 
“Localized drug delivery” is defined as a specific form of targeted delivery where the 
medication is given at a certain site which allows for reduced movement and subsequent 
absorption into the bloodstream. Localized delivery is often provided to a naturally 
enclosed space, such as the bladder or into the vitreous humor of the eye, but other 
techniques can limit movement such as a gel or patch. In general, by delivering a given 
pharmacological treatment to a specific target tissue site via an implantable pump or acute 
access, localized therapy will reduce systemic effects on peripheral tissue thereby limiting 
side effects, while maintaining increased control.  
Just as IV delivery increases control and decreases variability compared to oral delivery by 
eliminating the gastrointestinal tract, local delivery increases control and decreases 
variability by eliminating reliance on patient circulation for distribution. Thus localized 
drug delivery carries the potential for increased effectiveness of treatments, while reducing 
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the quantities needed (Figure 1). These reductions have important applied implications 
when one employs either drug pumps or impregnated gels to delivery therapies, as they can 
only hold limited volumes. 
Delivery Method Advantages Disadvantages
Targeted Drug Delivery 
Ultrasound or heat disrupted 
carriers 
non-invasive focal 
treatment to potential 
asymmetric areas 
equipment intensive, 
potential buildup within liver 
and spleen 
Biomarker targeted simple administration designer molecules need to 
be created, approved 
Localized Drug Delivery 
Pericardial delivery entire epicardium treated, 
well contained, easy access 
in surgery 
invasive, pericardium often 






Drug eluting wafers long or short lasting, 
tunable degradation 
minimal migration small 
doses, reliant on resorbable 
wafer or must be explanted 
Implantable pump local drug delivery on 
demand, larger continuous 
dosing possible 
invasive, needs refilling, 
shortcomings associated with 
implantable devices 
Coronary injection increases myocardial 
concentrations 
invasive/minimally invasive, 
treatment still enters blood 
Table 1. Various targeted therapies and their advantages and disadvantages. 
Finally, an additional benefit often seen with localized delivery is a relative increase in the 
therapeutic drug half-lives. For example, since localized treatments typically have minimal 
crossover with the patients’ circulation, there is limited exposure to their livers and kidneys, 
which are typical sites for drug metabolism. Thus the relative therapeutic half-lives of many 
pharmaceuticals will be increased, creating another mechanism to decrease the amount of a 
given agent required to achieve sustained therapeutic dose levels [7].  
While targeted drug delivery is the focus of broad research, it is our intent with this chapter 
to narrow the focus more specifically on localized therapy and the unique opportunities 
provided by the access obtained during thoracic surgery. For instance the pericardium 
surrounds the heart and provides a unique enclosed volume in which one can target the 
epicardial surfaces. In other words, the localized drug delivery to the pericardial space will 
allow the agent to diffuse into the myocardium while reducing those amounts present in the 
circulating blood. During cardiothoracic surgery one has unique access to this otherwise 
difficult to reach space where subsequent therapy can be delivered throughout the 
perioperative period. Therefore, as therapies emerge to treat heart failure, local delivery 
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during thoracic surgery is positioned to be a viable therapeutic option that can be delivered 
with minimal added time, as well as few complications or complexities. At the same time it 
has the potential to reduce ischemic damage and arrhythmias, and holds great potential for 
improved outcomes, reduced morbidity, and increased cardiac health. 
 
Figure 1. Schematic of differences in drug delivery by oral, IV or local delivery modalities. Increasing 
the number of transport steps increases the amount of drug necessary and patient to patient variability 
increases at each step. 
2. Known procedural complications and potential therapeutic 
opportunities 
Cardiac surgery is typically defined by a broad class of surgeries intended to correct heart 
problems. They can be broken down into several categories that include: 1) valve repair and 
replacements, 2) structural heart repairs, 3) implantations of devices for either the 
maintenance of rhythm or mechanical performance, and 4) heart transplants. Today, the 
most common cardiac surgery is coronary artery bypass grafting (CABG) [8]. Despite the 
recent trend towards minimally invasive cardiac procedures, there still remains a significant 
need for open surgical techniques. Due to the invasive, and many times emergent, nature of 
these procedures they are also excellent candidates for targeted delivery (it should also be 
noted that many minimally invasive and scheduled procedures could also take advantage of 
target therapeutic delivery of various agents).  
It is generally accepted that open cardiac surgery is not without potential complications. On 
the other hand, the occurrences of such complications can be viewed as unique 
opportunities for introduction of localized drug delivery to improve patient outcomes. It is 
important to note that complication rates and outcomes can only be truly assessed on both 
procedural and patient population bases; yet there are often common complications across 
all classes of cardiac surgery. Statistics on the following procedural complications and 
proposed treatments using targeted delivery will be discussed: neurologic, arrhythmic, 
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gastrointestinal, bleeding, and infection. These complications when present will impact both 
short- and long-term morbidity and mortality, i.e., influence length of hospital stays, quality 
of life, as well as financial burdens on both patients and healthcare providers. 
To begin with, neurologic complications such as stroke, post-operative cognitive deficit, 
encephalopathy, and transient ischemic attack are of particular concern because of their 
much feared, potential long-lasting effects. Due to the nature of cardiac surgery and 
cardiopulmonary bypass, it can be foreseen that thrombosis or air emboli may occur from 
time to time, potentially causing these aforementioned complications. Poor neurological 
outcomes may also be caused by or related to arrhythmias, bleeding, or other complications. 
For example, prospective studies on the outcome of CABG patients show that the expected 
stroke rates vary from 1.5% [9] to 5.2% [8]. A broad range of disorders fall under the 
umbrella of post-surgical encephalopathy, a syndrome stemming from many causes. Its 
prevalence has been described to vary based on the definition, with as many as one third of 
patients eliciting an encephalopathy post-operatively [10], but prospective studies show that 
by day four the number is reduced to 11.6% [11] indicating a transient nature. Expectedly, 
these complications occur more frequently in combined procedures and/or more technically 
challenging cases.  
It should be mentioned that numerous modern surgical techniques, such as the no-touch 
aorta technique, have attempted to mitigate such neurologic complications. However, it will 
likely remain that current advances in surgical techniques may only reduce, but not totally 
eliminate, these undesired events. Nevertheless, one can envision the added use of tailored 
drug cocktails with various procedures that could directly target the heart (pericardial 
space) or mix within the blood returning from cardiopulmonary bypass. To date, potential 
therapeutic agents which have been shown to be effective include: 1) oxide scavengers, 2) 
nitric oxide inhibitors [12], 3) agents to inhibit glutamate related neural excitotoxicity [13], 
and 4) the administration of aprotinin, a serine protease inhibitor [14]. It is possible that 
prior to patient rewarming, agents similar to tissue plasminogen activator could be 
administered in a manner that targets or localizes only the cerebral circulation and 
potentially destroys clots that were formed, thus mitigating negative effects prior to 
rewarming. 
It is generally considered that atrial fibrillation (AF) is the most common complication to 
occur after cardiac surgery, occurring in up to 30% of cases [15]. A recent meta-analysis of 94 
trials by Burgess and colleagues has shown that the five most common interventions were 
all effective at reducing the incidence of AF, but to varying degrees. These treatments 
included beta-blockers, sotalol, amiodarone, magnesium, and atrial pacing. It should be 
noted that amiodarone was the only intervention that was reported to reduce stroke on its 
own. Nevertheless due to the well documented negative systemic effects of such 
antiarrhythmics, several studies have begun to investigate the use of localized delivery to 
the pericardial space, discussed in more detail below. On the other hand, it should be noted 
that the systemic administration of modified agents could also prove effective and avoid 
side effects if targeting functionality was incorporated into the drug molecule. For example, 
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this could be done by adding cardiac specific antibodies or ligands to therapeutic molecules. 
Nevertheless, such newly developed drug isoforms will require additional regulatory 
approval, perhaps only after clinical studies prove them safe and effective.  
Gastrointestinal complications after cardiac surgery are less common, but importantly are 
associated with high rates of morbidity and mortality. Reported incidences are in range of 
<1%, but mortality associated with this complication is approximately 25% versus 
approximately 3% without gastrointestinal complications [16], [17]. The most common of 
these complications include: upper intestinal bleeding, intestinal ischemia, acute 
pancreatitis, and perforations.  
Despite the use of modern day antibiotics, infection still remains a prevalent problem in 
cardiac surgery, as does administration of blood products. The two are commonly 
interrelated and it has been shown that transfusions of packed red blood cells (PRBCs) are 
significantly associated with post-operative infections [18]. However, this correlation does 
not necessarily imply causation, and the use of PRBCs may be related to procedural 
difficulties, which may be the real underlying causation of such infection rates. It should 
also be considered that stored red blood cells also do not function normally, and therefore 
PRBCs may contain inflammatory and immuno-mediating substances. It was reported in a 
CABG patient series study at Duke University that as many as 39.5% of patients received 
PRBCs [18]. Furthermore, out of the entire series, the post-operative infection rate was found 
to be 6.2%; specifically, patients that received PRBCs elicited infection rates ranging from 6-
8.1% versus 5.1% for those who received no PRBCs [18]. Additionally, in a recent five-year 
study on long-term survival following transfusion for CABG procedures, it was observed 
that patients not transfused have approximately 2.5-fold better survival rates than those that 
did [19].  
Interestingly, it has been proposed that actively targeted treatments could possibly restore 
normality to the RBCs prior to administration; such treatments could also incorporate anti-
infection components. As mentioned above, RBCs can change drastically and immediately 
upon storage. It is considered that due to the low oxygen environment within the blood 
collection bag, RBCs switch to anaerobic metabolism, which in turn leads to lactic acid 
buildup and an overall reduction in blood pH. Furthermore, it is known the RBCs lose their 
signature bi-concave shape and become more spherical with storage; recall that it is this bi-
concavity that is necessary for the cells to efficiently travel through capillary networks. 
Stored RBCs will also form aggregates due to activated surface proteins by crosslinking 
fibrinogen between GPIIb/IIIa binding sites [20]. This crosslinking increases the longer 
PRBCs are stored, and potentially could contribute to neurologic complications and thus 
post-operative cognitive deficits. Therefore, one could consider that prior to infusion of 
PRBCs, a targeted drug cocktail could be added to prevent or break these fibrinogen 
crosslinks and/or suppress immuno- and inflammatory effects. 
Finally, one should also consider that infection rates could potentially be reduced by 
localized drug delivery at the end of a given cardiothoracic surgical procedure. For example, 
one such method might take the form of an antibiotic that could be sprayed on or within the 
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thoracic cavity immediately prior to and after closure of the surgical entrance site. Such an 
application method may also have the potential to reach interstitial areas that are at risk for 
infections, specifically those with inherently minimal blood flows; in other words, these 
tissue areas would otherwise receive minimal amounts of orally or intravenously 
administered antibiotics. 
2.1. Other drug targets 
With recent advances in microfabrication, it is feasible to locally deliver drugs in ways that 
were previously not possible. The field capsule endoscopy is a good example of these 
technologies and also one that may be further miniaturized and exploited for drug delivery. 
“Capsule endoscopy” is the swallowing of a pill with a video camera inside. The pill travels 
through the gastrointestinal system and records its journey. Even more sophisticated 
versions of these devices are being developed to be actively propelled by magnetic energy 
[21] or flagella type [22] propellers. It should also be noted that magnetic pills for drug 
delivery are currently under development [23]. One should consider that these novel 
technologies may also be exploited for cardiac use. For example, a patient could have a 
magnetic pill guided endovascularly to the heart and anchored to the endocardial surface 
where therapeutic (biologics or drugs) agents are released. Furthermore, one could even 
envision that the administration of these therapeutics could be controlled wirelessly and 
facilitated by micropumps and valves.  
In the near future, it is considered that drug eluting microfabricated devices with 
incorporated biosensors could be implanted locally such that they release drugs in response 
to given physiological stimuli. For example, a small sphere, capsule, or micelle containing 
insulin producing cells could be implanted in the pancreas, subdermally, or 
intramuscularly. The cells could then respond to fluctuations in glucose levels 
automatically. Extensive research has gone into such closed loop systems for insulin 
delivery for diabetes patients, with the eventual goal of developing an artificial pancreas 
[24–27]. In the more distant future, genetically engineered cells could be programmed to 
produce other drugs as needed and subsequently deliver them at the proper rates or in 
response to particular stimuli. Furthermore, unlike implantable devices such as drug eluting 
stents that can only deliver drugs for a few years, these cell-based drug producing devices 
have the potential to last a lifetime.  
It is generally considered that delivering therapeutic agents at or near the entrance to 
coronary arteries would be particularly useful in certain clinical situations. Such delivery 
methods could then exploit the natural capillary system to perfuse the drug to the entire 
heart. This could in turn potentially reduce the amount of drugs needed significantly and 
may also ameliorate undesired side effects known for systemic administration. In another 
approach, during surgical operations, deployed degradable microcapsules with tuned drug 
release profiles could be injected into the myocardium adjacent to the coronary arteries. 
Alternatively, resorbable patches could be adhered over the main coronary arteries and the 
therapeutic agent would then diffuse into the vessel and be transported to the entire organ. 
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In addition, a delivery patch could also be adhered to local areas, such as one doped with 
angiogenic treatment placed on an infarct zone. 
In the future, combinatorial therapies could also be extended beyond current clinical 
practice such as drug eluting stents and pacing leads. This is an area of great opportunity for 
local drug delivery advancements. For example, ventricular assist devices could incorporate 
the ability to passively or actively deliver a variety of therapies. As such, their possible 
approaches and advantages may improve the use of these devices, e.g., when they are being 
used as a bridge to transplant or recovery.  
It should be noted that the direct injection of drugs, proteins, or cells into the myocardium 
has also been proposed as a method of local delivery [28–31]. More specifically, these could 
be localized in areas of infarct or near atherosclerotic plaque deposits to aid in restoration of 
normal function. To date, it is noteworthy that positive results have been observed with 
injections of adenoviruses encoding for heat shock protein [28] or growth hormone [29], [30] 
in rabbit and rat models, respectively. Furthermore, clinically, gene transfer by direct 
injection of plasmid DNA coding vascular endothelial growth factor (VEGF) into ischemic 
myocardium has promoted angiogenesis [31]. 
It should be described for completeness that transmyocardial laser revascularization has 
been applied clinically to patients with inoperable coronary artery disease and often used in 
conjunction with CABG. This procedure utilizes a laser to perforate the walls of the heart in 
areas of poor perfusion. The channels created act as conduit for blood and, during healing 
neovascularization, and also considered to improve perfusion. Perhaps this approach, if 
considered an option, could be supplemented with adjuvant use of local therapeutic agents 
to quicken the vascularization process, such as VEGF, or other therapeutics to potentially 
restore normal function. 
2.2. Alternative local delivery methods 
To date, numerous drug pumps and other devices and methods for delivering treatment to 
a localized area or region of the body have been shown to be successful. As mentioned 
previously, there is a considered difference between local delivery and targeted delivery of 
treatments. Additionally, it is also possible that various therapeutic approaches incorporate 
one or both of these methods, in order to maximize the beneficial effects of the therapy and 
minimize the adverse side effects.  
One such method, which has been studied significantly, is to create a polymer or biological 
scaffold in which the drug/protein has been embedded. Subsequent release is then 
dependent upon either degradation of the scaffold or diffusion of the drug out of the 
scaffold. Currently there are clinical devices available, such as the Gliadel® wafer, which is 
impregnated with a chemotherapy drug and used following surgical resection of cancerous 
tissue within the brain [32], [33]. Note that these drug delivery platforms have been made 
from a number of different polymers, synthetic or natural. Ultimately it is considered that 
whichever material is used, it must be biocompatible and able to dispense the drug at 
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appropriate rates for the particular treatment. Currently, such products have been 
developed relative to treatments for cancers, which have included polymer structures for 
subcutaneous or intramuscular placement. More recently, similar scaffolds have been 
created for the treatment of cardiac diseases, but these are still within the research phase of 
the design.  
Myocardial patches, often made of a gel, collagen, or other biocompatible material, are 
typically impregnated with stem cells or protein growth factors meant to diffuse into the 
heart to promote myocardial growth and revascularization. These are placed locally on 
infarcted areas of the heart. Alternatively, the scaffolds could be designed to promote 
growth within their structure, becoming a functioning part of the myocardium. If the 
device/scaffold is made such that it requires stem cell infiltration in an in vitro setting, it can 
be incubated with the particular cells needed prior to implantation onto the cardiac 
structure [34]. Both of these methods illustrate how tissue engineering approaches could be 
utilized to locally deliver drugs or therapies to the heart, however there are other 
mechanical devices that also allow a physician to deliver drugs directly to the site of interest.  
2.3. Localized injections and drug pumps 
When discussing localized treatment of tissue, a method to deliver the treatment to a 
specific region of interest is essential. Various methods have been reported in the literature, 
from simplistic methods of direct injections of the drug to the localized area to be treated to 
the use of more complex microelectromechanical systems (MEMS). The method for direct 
injection of a treatment into a specific diseased area is a fairly simplistic idea; however, the 
means to deliver a needle and treatment to the heart may pose a significant challenge. 
Current research is investigating injections into the myocardium via angioplasty balloons to 
reduce the occurrence of restenosis. More specifically, small pores or openings within a 
catheter deliver gene therapy or alternative drug treatments to the diseased cardiac cells 
[35], [36]. Likewise a given drug can be coated directly onto the exterior surfaces of a 
balloon, i.e., when the angioplasty is performed, the coating rubs off on the wall of the 
vessel to provide therapy. Recently, Scheller and colleagues demonstrated that such a device 
was able to decrease the incidence of restenosis significantly [37]. Stents themselves can also 
be thought of as a method for localized delivery of a drug to a specific location. This 
approach has been well developed and tested; drugs like paclitaxel have been coated onto 
the outside of a coronary stent to minimize restenosis that can occur at sites of stent 
implantation [38]. 
Other treatments that might be administered to a patient may need to be localized, but cover 
a greater area than a single location along an artery or vein. For those purposes, devices 
such as MEMS or osmotic pumps could perhaps be utilized to slowly deliver treatment to a 
specific site continuously or intermittently and with varying rates; i.e., delivery could last 
from days to months. When considering drug pumps, they generally fall into one of two 
categories, passive or active. The passive pump approach can be thought of as being similar 
to the gels or wafers discussed previously; however instead of the drug being embedded 
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within the polymer, it would be contained within a chamber that would be opened once the 
polymer had been degraded enough to release it. To date, several designs have been 
implemented including multiple wells in a row with differing polymer closures to release at 
different times, as well as multiple chambers to release two different types of drugs 
simultaneously. As one could imagine, the only limitations to these types of designs are the 
properties of the polymers and the size of the device [32], [39].  
One specific design described as a passive system is fairly unique- the use of osmotic 
pressure to push out the drug from a syringe-like device. These work on the principle that 
water will diffuse one way across a semipermeable membrane and increase the pressure on 
one side, thereby pushing out the drug slowly [39]. These types of devices have also been 
modified slightly to create pulsatile drug delivery pumps, i.e., in one case, a membrane was 
set up and had immobilized glucose oxidase which converted glucose to gluconic acid [40]. 
This results in an ionic change in the membrane, and the electrostatic repulsion of the 
membrane causes an expansion and increased delivery of insulin. This has the added ability 
to adapt to the specific needs of patients at various times of the day, depending upon 
glucose levels within their systems [40].  
Another type of the MEMS approach for agent delivery is to release a bolus from a small 
reservoir; initially these devices relied on an electrochemical dissolution of a gold membrane 
blocking a reservoir of a solution. However, a number of published studies to date have 
reported that this approach could not be performed reliably, so it was modified to a 
localized melting of the gold membranes by resistive heating [32]. Another approach of an 
active delivery pump has been employed for patients with chronic pain, e.g., a pump with a 
reservoir filled with a pain medication can be implanted with a catheter leading directly into 
the spinal column or other neuronal targets. It should be noted that more recently the ability 
to refill these devices has been greatly improved and this is an advantage over MEMS 
devices that cannot refill, however the size of the former devices are currently much greater 
[41]. These types of pump systems have their own specific purposes, yet both intend to 
deliver a drug treatment to a localized area within the body to help reduce the effects of the 
drug on other organs or nearby healthy tissue.  
2.4. Ultrasound and lipisomal delivery approaches 
Another delivery technique is encapsulating agents for release in specific areas. As opposed 
to the local delivery pumps described above, where a drug is released into a specific location 
within the body, generally these packaged therapies can be administered intravenously with 
targeted release. In these cases, the drug will circulate throughout the entire body, but 
importantly the targeted drugs have been altered in a way to make them: 1) released at a 
specific site, 2) preferentially bind within the diseased area, 3) be more readily taken up by 
the target cells, 4) preferentially released slowly over time, or 5) any combination of these 
attributes. Ultimately the aim is to increase the effectiveness of the treatment while 
decreasing the toxic systemic effects of the drug. These approaches can be considered 
compatible with localized delivery, especially in the setting of thoracic surgery. For instance, 
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a targeted drug could be infused into the coronary arteries, compounding the targeted 
design with local delivery. 
Another specific way that investigators have been able to achieve targeted delivery is by 
using liposomes that encapsulate the drug, relying on active or passive targeting of tissues to 
be treated. First, it can act passively, relying on various cells to uptake the liposomes, e.g., 
reticuloendothelial cells, which can be found concentrated within the liver and spleen. Thus if 
the treatment was designed specifically for cells within the liver or spleen, a passive approach 
might be quite acceptable. It should be noted that this same approach has been discussed 
within nanoparticle delivery as well, taking advantage of the fact that the vasculature within 
tumors can be porous, allowing the nanoparticles to accumulate within the tumor region. It is 
still important, however, to aim to limit peripheral exposure, since such liposomes may still 
be taken up within the liver and other filtering organs [39], [42].  
More specifically, an active targeting paradigm could be achieved by placing a recognition 
sequence on the outside of the liposome, to develop ligand-receptor interactions that will in 
turn bind the carrier to the targeted cells. As such, these could be targeted to specific 
proteins or to biomarkers that are upregulated in specific tissues, like tumors or portions of 
the myocardium responding to ischemia or heart failure [2], [3]. One needs to consider that 
these modified liposomes may still be taken up by the liver, spleen, or other non-targets; 
however, some specified modifications of the developed lipid layers may minimize uptake 
in these structures [42].  
Another reported means that treatments may be delivered to target specific cells is via 
microbubbles aided by ultrasound disruption. More specifically, the microbubbles can be 
formed by air or other types of gas and introduced into the bloodstream similar to those 
techniques utilized in ultrasound imaging with contrast. Note that air bubbles are more 
readily dissolved into the blood following introduction into the venous system, giving them 
a shorter lifespan. By using perfluorocarbon gases, the lifespan of the delivery bubbles 
increase and they can also be coated with a variety of materials including polymers, lipids, 
or proteins which will further increase the lifespan. These longlasting microbubbles can then 
be disrupted by focused ultrasound—a trigger that can be applied nearly anywhere in the 
body [4–6]. It is considered that the ballistics of the cavitation not only disrupt the integrity 
of the bubble, but it will also momentarily disrupt the plasma membranes of the target cells, 
allowing for the drug and/or microbubbles to be passed through [43]. While this approach 
has resulted in detrimental effects on cardiac mechanical function [44], it has been shown to 
effectively increase absorption of certain drugs [43]. Alternatively, the capsules can be 
designed to release their therapeutic payload with a slight increase in temperature that can 
be triggered by local heating [45].  
3. Pericardial delivery 
It has been noted that the pericardium provides a unique space that holds a vast potential 
for localized drug delivery. For example, such pericardial approaches may range from: 1) 
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the delivery of preconditioning therapies during surgical preparation, 2) providing for 
therapies that promote vascular genesis after CABG, and 3) the prophylactic administration 
of antiarrhythmic agents in order to prevent post-operative AF. We believe that the possible 
treatments for the myocardium are numerous and will provide a few specific examples 
below, following a review of pericardial anatomy. 
3.1. Anatomy of the pericardium 
The pericardium is made up of two connected structures. The innermost layer is serous 
membrane which is inseparable from the epicardial surface, and is called the “visceral 
pericardium.” The continuous serous membrane is folded in on itself and the single layer also 
makes up the inner surface of the parietal pericardium. The single layer of mesothelial cells is 
indistinguishable from the fibrous outer layer (Figure 2). Together, the parietal and fibrous 
layers make up the outer layer, or “parietal pericardium.” This is the most prominent layer of 
the pericardium and is what we generally think of when we discuss the pericardium.  
 
Figure 2. Schematic of the layers of the pericardium. The upper right shows a schematic diagram of the 
serous and fibrous pericardium with respect to the heart. The expanded cross-section view shows the 
attachment of two layers of the serous pericardium (visceral and parietal) to the myocardium and 
fibrous pericardium, respectively.  
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The healthy pericardium contains 20-60 mL of pericardial fluid. This fluid, an ultrafiltrate of 
the plasma [46], surrounds the heart, with the majority concentrated in the pericardial 
sinuses and atrioventricular grooves. This fluid normally drains into the lymphatic system 
at a relatively slow rate, measured to be a volume equivalent to every 5-7 hours in sheep 
[47]. However, as pericardial fluid pressure increases, such as in the case of cardiac 
tamponade, investigators have found that not only does lymphatic drainage increase [48], 
but fluid may pass through the pericardium and enter the pleural space [49]. 
Though the volume of pericardial fluid is not evenly distributed, it is generally found to be 
well mixed due to the motion of the heart; thus agents can be considered to be quickly and 
evenly dispersed throughout [47]. Even though there is only a relatively small amount of 
fluid circulating around the ventricles, this aforementioned mixing action will help maintain 
even distribution of any additions to the pericardial fluid epicardially, thus maintaining 
consistent gradients relative to the myocardium. While the parietal pericardium is generally 
considered as non-compliant, the overall pericardial space can accommodate moderate 
increases in the amount of fluid by filling in the pericardial sinuses. However, once this 
reserve volume space is filled, pericardial pressure quickly increases with added volume, 
i.e., symptomatic tamponade is elicited (Figure 3). 
 
Figure 3. Percardial pressure vs. pericardial volume. As pericardial fluid volume increases, the 
pericardial reserve volume is filled. Once the reserve volume is full, pressure within the pericardium 
rapidly rises causing cardiac tamponade and functional depression. 
3.2. The basic physiology associated with the pericardium 
The fibrous (parietal) pericardium is 1-3 mm thick in healthy humans, and as noted above, is 
considered as minimally or non-compliant. In fact, because of these features, multiple 
bioartificial replacement heart valves are made with leaflets of either bovine of swine 
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pericardium. As such, this tough layer has the primary function to physically constrain the 
heart. While this may not have a large influence at rest, during physical exertion, cardiac 
filling becomes limited by the pericardium. Further, it has been noted that an intact 
pericardium also increases cardiac chamber interdependence, i.e., increased pressure in one 
chamber affects other chambers because the total volume is restricted by the pericardium. A 
more detailed review can be found in the Handbook of Cardiac Anatomy, Physiology, and 
Devices [50].  
Typically during cardiothoracic surgery, the pericardium needs to be opened to obtain 
direct myocardial access, and at the end of a procedure the pericardium is not typically 
closed. This in turn reduces the risk of post-surgical cardiac tamponade, as pressure cannot 
build up easily in an open pericardium. However, the lack of a barrier between the heart 
and the healing incision site typically leads to scarring and epicardial fusions within this 
wound site. Typically, this has minor consequences—that is until a subsequent open-heart 
procedure needs to be performed — and both the initial incisions and heart access are 
complicated by these additional fibroses. It has been suggested that a barrier placed between 
the sternum and myocardium would potentially limit the buildup of subsequent adhesions 
and make reentry less risky. While synthetic barriers such as the absorbable CovaCard 
(BIOM’UP, Lyon, France) are being developed [51], the native or graft pericardium also may 
provide a natural and available option. 
Relative to physiological consequences, in addition to reducing reoperative complications, 
the closure of the pericardial sac following cardiac surgery has been proposed to reduce 
long-term cardiac performance and aid in maintaining diastolic function and ventricular 
geometry, as well as reduce right ventricular dysfunction [52], [53]. Additionally, one could 
also consider that a closed pericardium may also provide a reservoir space for subsequent 
pericardial therapies. Yet, one reported limitation to pericardial closure is that it can acutely 
reduce cardiac indices and stroke work [54]. More specifically, Rao et al. corroborated that 
these functions were reduced one hour post-operatively in patients who had pericardial 
closure (P<0.001). However, they also reported no significant differences in function 
between patient groups at 4 hours or 8 hours post-operatively. While increased risk of 
cardiac tamponade still exists with full closure, it has been reported that fenestrated 
techniques and pericardial drainage tubes have been used to mitigate the consequences of 
pericardial effusions [55], [56]. 
In summary, the pericardial space potentially provides a natural barrier and is well suited for 
localized drug delivery. Thus if pericardial access could be easily and reproducibly obtained, 
the possibilities of long- and short-term treatment include: antiarrhythmic therapies, delivery 
of agents to reduce cellular injuries at reperfusion, and/or use of angiogenic proteins to 
promote revascularization and regrowth specifically within infarcted regions. 
3.3. Cardioprotective agents 
To date within the US, ischemic heart disease and myocardial infarctions remain as leading 
causes of clinical morbidity and mortality. Their occurrence often leads to congestive heart 
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failure, which in turn causes further reductions in coronary flow and necrosis in the 
myocardium, and leads to further functional impairments. It is generally considered that 
compared to other body tissues, myocardial cells have poor regenerative abilities, a fact that 
has focused much research on methods for reducing trauma and/or myocardial death, as 
well as methods for improving repair and regeneration. 
It has been reported that the local infusion of nitric oxide donors could promote local 
vasodilation without major systemic effects [57]. Additionally, the administration of VEGF 
and other angiogenic agents into the myocardium have been associated with several 
benefits that include: increased collateral vessel development, increases in regional 
myocardial blood flow, improved myocardial function in the ischemic regions, and/or 
increased myocardial vascularity [31], [58–60]. 
Relative to cardioprotective agents, our laboratory has observed that intrapericardial 
delivery of omega-3 polyunsaturated fatty acids can dramatically reduce both infarct sizes 
and ventricular arrhythmias associated with ischemia. More specifically in this study, acute 
ischemia was induced for 45 minutes followed by 180 minutes of reperfusion, while the 
omega-3 fatty acid docosahexaenoic acid (DHA) was delivered to the pericardial space prior 
to ischemia as well as during the initial period of reperfusion. Importantly during the 
ischemic period, ventricular arrhythmias were reduced 50% (which in the control hearts 
required defibrillation and caused 20% mortality). Upon completion of the reperfusion, the 
hearts were excised and ischemic damage was measured; hearts treated with DHA had a 
similar area at risk, but a 57% reduction in normalized infarct size was seen [61]. Ongoing 
research in our lab also suggests that omega-3 fatty acids may reduce susceptibility to AF 
during cardiac surgery. 
Most recently, investigations in our laboratory have explored the pericardial delivery of 
specified bile acids noted to have anti-apoptotic benefits. These molecules are upregulated 
within hibernating black bears, and reports by others have suggested that ursodeoxycholic 
acid may be beneficial in reducing AF within myocytes [62]. In these ongoing studies to 
determine potential beneficial effects within a large animal model, we specifically deliver a 
taurine conjugate of ursodeoxycholic acid within a formed pericardial cradle (the pericardial 
space) and periodically induce AF. Preliminary results have suggested that these molecules 
are effective in reducing the times a given heart will elicit AF, i.e., without having to give 
this therapy intravenously and thus potentially have undesirable systemic side effects 
(unpublished data).  
3.4. Antiarrhythmic agents 
Antiarrhythmic drugs are commonly known for their narrow therapeutic ranges and severe 
side effects. It has been previously suggested that delivery of these agents to the pericardial 
space would allow for myocardial diffusion while lowering undesired plasma drug 
concentrations [63], [64]. In other words, such local delivery allows for higher doses of this 
class of agents to be safely administered to control focally the heart rhythm—an application 
that could be especially applied during cardiothoracic surgery. To date, the intrapericardial 
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delivery of antiarrhythmic agents has been attempted with numerous agents, e.g., esmolol 
[63], solatol [65], atenolol [65], ibutalide [66], procainamide [67], [68], digoxin [67], 
amiodarone [69], arachadonic acid [70], nitroglycerin [57] and L-arginine [71] have all been 
shown to have electrophysiological effects when delivered to the pericardial space in 
various animal models. Additionally, in those studies that also measured plasma 
concentrations, there was minimal crossover of the delivered agent into the bloodstream 
[67–69] 
To date, despite these reported successes in treating arrhythmias in various animal models, 
the clinical practice of intrapericardial (IP) delivery is not widely employed. Possible 
reasons include: 1) the lack of experience (no large clinical trials), 2) difficulties with access 
and removal of agents, and/or 3) unknown potential complications with this delivery 
route. It is important to note that one of the described major concerns with pericardial 
delivery is that it relies primarily on trans-epicardial diffusion to reach the myocardium. In 
other words, while the thin atria and superficial sinoatrial node may be easy to treat via 
these mechanisms, the effects of possible ventricular drug gradients are not well defined. 
Further, it has been hypothesized that moderately soluble or lipophilic molecules will not 
be evenly transported across the thicker ventricles, causing various degrees of 
electrophysiological changes through the depth of the myocardium, creating a scenario 
where the epicardium and endocardium are not conducting and/or contracting at similar 
rates. This electrical heterogeneity theoretically carries the possibility of initiating, rather 
than inhibiting, arrhythmias [68]. 
In our lab, we have investigated the pharmacokinetics and pharmacodynamics of IV and IP 
delivery of metoprolol [7]. While the β-blocker is typically used to treat angina and 
hypertension, it is also used to treat tachycardias. With a tachycardic swine model, IV 
delivery of metoprolol was faster acting compared to IP, but only by several minutes. While 
the reductions in heart rates were similar for both delivery techniques, these effects were 
sustained longer after IP delivery. Importantly, IV delivery was accompanied by significant 
reductions in contractility, while IP delivery elicited minimal effects. In other words, these 
findings indicated that IP delivery of metoprolol may have similar bradycardic effects 
compared to IV delivery, but without the reduced contractility. The other important finding 
in this study was the minimal pericardial crossover of metoprolol within blood, as well as 
the slightly increased half-life of the drug [7]. 
3.5. Clinical pericardial access 
Access to the pericardial space for the delivery of therapies outside of cardiothoracic 
surgical procedures may pose many difficulties. However, multiple minimally invasive 
procedural methodologies are under development. For example in the trans-atrial approach, 
access to the pericardium is achieved via a catheter coming up through the femoral vein into 
the right atrial appendage, where it then punctures through this thin myocardium to gain 
access into the pericardial space. To date, success with this approach has been demonstrated 
in canines and swine [72]. Alternatively, a subxyphoid access procedure has been suggested 
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[73]. While this method is often used to drain the pericardial space during episodes of 
cardiac tamponade, the minimal separation between the fibrous pericardium and the 
epicardium make this approach more difficult when there is not a substantial amount of 
intrapericardial fluid present. Several access tools have and continue to be developed to aid 
in subxyphoid access using minimally invasive approaches. For instance, the PeriPortTM 
(Cormedics, TX) system is designed to initially enter the thoracic space through a 
subxyphoid incision, where it uses a vacuum on the distal end to grip the pericardium and 
separate it from the heart’s epicardial surface. Once the pericardium is pulled into the 
vacuum chamber, a retractable needle pierces the pericardium and allows for a near 
tangential entrance of a guidewire. Such designed access tools should enhance the safety 
and simplicity of pericardial access and also have potential to increase the widespread use 
of localized therapies to treat pericardial and cardiac diseases. Nevertheless, during 
cardiothoracic surgery, a simple syringe or perfusion pump is all that is clinically needed to 
deliver pericardial therapies. Thus the hurdles to add localized pericardial delivery of drugs 
concurrent to surgery are much less compared to pericardial therapies on their own.  
  
Figure 4. Methods of pericardial access include the pericardium as a reservoir. Pictured here is a 
pericardial cradle in a swine model.  
3.6. Protocols 
As noted above, the pericardial delivery of molecules, cells, nanoparticles, etc., becomes 
simplified with surgical access (Figure 4). Without the requirement of added procedures and 
incisions, the pericardial delivery of therapeutics can be administered with minimal 
additional equipment, time, or complications, leading to numerous clinical scenarios that 
may benefit from the use of pericardial delivery. While some of these applications, as 
described below, have been tested in pilot studies in animals, future clinical studies have yet 
to be developed to confirm efficacy. 
In one such application, a common first choice of donor vessel for a CABG procedure is the 
internal thoracic artery. Thus, while the surgeon initially frees and prepares this vessel for 
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subsequent grafting, the pericardial administration of either a prophylactic antiarrhythmic 
or angiogenic agent could be infused into the pericardium. Once the artery has been 
prepared and the pericardium is further opened, the drug has a chance to partially diffuse 
into the myocardial tissue. Additional drugs could also be added through direct myocardial 
injection to promote revascularization or prevent post-operative arrhythmias. Alternatively, 
a procedure that requires access from the anterior surface of the heart may make use of the 
reservoir created by the remaining pericardium to treat the posterior myocardium during 
the procedure.  
Another important approach to consider is the post-operative administration of drugs, 
which could be accomplished via surgically placed pericardial drainage catheters. More 
specifically, with the placement of pleural drainage catheters and temporary pacing leads at 
the end of a procedure, the addition of a catheter leading into the pericardium is sometimes 
included [74]. This catheter, whether through the main lumen or a second lumen, could 
hypothetically allow for continued access to the pericardial space and delivery of 
appropriate antiarrhythmic, antibiotic, or other therapies to the myocardium. Therapies 
with such devices have been attempted with success in a porcine model [75]. 
As mentioned above, multiple techniques exist for low or no tension pericardial 
closures [56], [76], [77]. In addition to reoperative benefits, the planned closure of the 
pericardium can create a useful reservoir for localized treatment. While the most 
common clinical reason for non-closure is to reduce the risk of cardiac tamponade, this 
could be mitigated with the placement of the aforementioned specially designed 
drainage/therapy delivery catheter. We also believe that with full pericardial closure 
and access via the pericardial drain, a delivered therapy would reach all surfaces of the 
heart. 
Another clinical situation/option for localized drug delivery might be during 
cardiopulmonary bypass procedures. To arrest the heart and often throughout the 
procedure, cardioplegia solutions are perfused through the coronary vessels. Whether 
antiegrade or retrograde, this perfused solution cools and protects the heart by minimizing 
metabolism. It has been considered that myocardial damage can be further reduced by 
introducing cardioprotective agents via this delivery route [78–80]. It is important to note 
that in this unique situation, any administered drug reaches the entire myocardium via the 
capillaries, but will have no access to other tissues until after cross clamping is released. In 
other words, high transmural and widespread myocardial concentrations can be achieved 
with remarkable speed and accuracy while minimizing side effects. 
Similarly, organ transplantation offers ultimate accessibility in localized drug delivery. A 
typical transplant, includes explant, transportation and re-implantation. Because of the 
recovery of multiple organs, localized delivery is a viable option where the effects can be 
greatly enhanced after re-implantation function. Not only are options such as pericardial 
delivery still available since the heart is typically the last organ removed, but IV therapies 
just prior to cross-clamping become targeted.  
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Next, the times between explant and implant can range from under six hours for the heart 
to up to 24 hours for the liver or kidney. During these times, the heart is often in stagnant 
cold storage. However, ideas and methods for continuous perfusion during the 
hypothermic period are well established, e.g., continuous hypothermic perfusion of the 
heart was first applied only a year after the first successful human heart transplant [81]. 
Since then it shown that it is possible to keep large mammalian hearts viable for up to 48 
hours in baboons and swine [82], as well as improve function compared to non-perfused 
hearts [83]. While continuous hypothermic perfusion is not used clinically with heart 
transplantation, it should be noted that the Organ Care System (Transmedics, Andover, 
MA) gained investigational device exemption status in 2007, and a clinical trial is 
currently underway. This continuous perfusion during transport before implant provides 
another opportunity for localized therapies, as they could be simply added to the 
perfusates. 
4. Limitations and conclusions 
Localized delivery methods such as those into the pericardial space are not without 
potential limitations. Without direct access to the bloodstream, an administered agent at a 
target tissue, such as in the pericardial space, must diffuse into the target tissue to increase 
concentrations. While this may ultimately limit the depth or distance a given therapeutic 
agent (drugs, cells, nanoparticles, etc.) might be able to migrate in a significant quantity, it is 
also one of the major advantages of localized therapies.  
Some areas for localized treatments, especially within the myocardium, may be considered 
as relatively difficult to access. However, with a large number of cardiac surgeries currently 
being performed and an increasing number of catheter procedures being developed and 
implemented, these therapeutic methods could piggyback on planned procedures with few 
added complications or risks. Finally, novel therapeutic deliveries, drugs, or other 
interventions may need to gain additional approval in order to become indications for 
localized delivery.  
Cardiothoracic surgeries may facilitate novel opportunities for local drug delivery, such as 
overcoming the hurdle to obtaining pericardial access. Such clinical procedures also provide 
opportunities for localized injections or coronary infusions. The future opportunities for 
such therapies are not limited to the duration of the operation; by leaving a pericardial 
drainage catheter with delivery features, physicians could also incorporate subsequent 
therapeutic delivery. In some cases, implantable drug pumps or biodegradable patches 
could provide therapy to the patient beyond their ICU stay. The emerging field of localized 
therapy delivery shows great potential, but future human studies are needed to verify the 
positive results observed in pre-clinical studies. Nevertheless, the unique access afforded by 
cardiothoracic procedures may speed up implementation of these promising local and target 
therapeutic delivery methods, thus placing surgeons at the cutting edge of novel delivery 
approaches. 
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